171 related articles for article (PubMed ID: 22214810)
1. The effects of disease modifying anti-rheumatic drugs on osteoclastogenesis and bone destruction in rheumatoid arthritis.
Nanke Y; Yago T; Kotake S
Nihon Rinsho Meneki Gakkai Kaishi; 2011; 34(6):493-500. PubMed ID: 22214810
[TBL] [Abstract][Full Text] [Related]
2. Scientific basis for the efficacy of combined use of antirheumatic drugs against bone destruction in rheumatoid arthritis.
Suematsu A; Tajiri Y; Nakashima T; Taka J; Ochi S; Oda H; Nakamura K; Tanaka S; Takayanagi H
Mod Rheumatol; 2007; 17(1):17-23. PubMed ID: 17278017
[TBL] [Abstract][Full Text] [Related]
3. [Disease modifying antirheumatic drugs with inhibitory effect on osteoclastogenesis].
Urushibara M
Nihon Rinsho; 2005 Sep; 63(9):1615-9. PubMed ID: 16164220
[TBL] [Abstract][Full Text] [Related]
4. [Mechanism of bone destruction in rheumatoid arthritis and perspectives of the treatment].
Koyama T; Tanaka S
Clin Calcium; 2016 May; 26(5):735-41. PubMed ID: 27117620
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of disease modifying anti-rheumatic drugs on bone destruction in rheumatoid arthritis].
Tsuji H; Mimori T
Clin Calcium; 2015 Dec; 25(12):1835-42. PubMed ID: 26608859
[TBL] [Abstract][Full Text] [Related]
6. Skeletal complications of rheumatoid arthritis.
Heinlen L; Humphrey MB
Osteoporos Int; 2017 Oct; 28(10):2801-2812. PubMed ID: 28779302
[TBL] [Abstract][Full Text] [Related]
7. Metformin one in a Million Efficient Medicines for Rheumatoid Arthritis Complications: Inflammation, Osteoblastogenesis, Cardiovascular Disease, Malignancies.
Rajaei E; Haybar H; Mowla K; Zayeri ZD
Curr Rheumatol Rev; 2019; 15(2):116-122. PubMed ID: 30019648
[TBL] [Abstract][Full Text] [Related]
8. [Secondary osteoporosis. Bisphosphonates as a possible strategy for the prevention of bone destruction in rheumatoid arthritis].
Suzuki Y
Clin Calcium; 2007 Dec; 17(12):1909-13. PubMed ID: 18057668
[TBL] [Abstract][Full Text] [Related]
9. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
10. Requirement of methotrexate in combination with anti-tumor necrosis factor-alpha therapy for adequate suppression of osteoclastogenesis in rheumatoid arthritis.
Matsuno H; Yoshida K; Ochiai A; Okamoto M
J Rheumatol; 2007 Dec; 34(12):2326-33. PubMed ID: 18050387
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination therapy for preventing bone damage in rheumatoid arthritis.
Iannone F; Lopalco G; Cantarini L; Galeazzi M; Lapadula G
Clin Rheumatol; 2016 Jan; 35(1):19-23. PubMed ID: 26581205
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional Regulation of Osteoclastogenesis: The Emerging Role of KLF2.
Rolph D; Das H
Front Immunol; 2020; 11():937. PubMed ID: 32477372
[TBL] [Abstract][Full Text] [Related]
13. IL-6 signal blockade ameliorates the enhanced osteoclastogenesis and the associated joint destruction in a novel FcγRIIB-deficient rheumatoid arthritis mouse model.
Ohtsuji M; Lin Q; Nishikawa K; Ohtsuji N; Okazaki H; Tsurui H; Amano H; Shirai T; Nishimoto N; Nishimura H; Hirose S
Mod Rheumatol; 2015 Mar; 25(2):270-7. PubMed ID: 25159156
[TBL] [Abstract][Full Text] [Related]
14. [ Bone and cartilage destruction in RA and its intervention. Disease-modifying antirheumatic drugs].
Ichikawa N; Yamanaka H
Clin Calcium; 2012 Feb; 22(2):215-21. PubMed ID: 22298075
[TBL] [Abstract][Full Text] [Related]
15. Novel therapies for rheumatoid arthritis.
Tremoulet AH; Albani S
Expert Opin Investig Drugs; 2006 Nov; 15(11):1427-41. PubMed ID: 17040201
[TBL] [Abstract][Full Text] [Related]
16. META060 inhibits osteoclastogenesis and matrix metalloproteinases in vitro and reduces bone and cartilage degradation in a mouse model of rheumatoid arthritis.
Konda VR; Desai A; Darland G; Bland JS; Tripp ML
Arthritis Rheum; 2010 Jun; 62(6):1683-92. PubMed ID: 20201075
[TBL] [Abstract][Full Text] [Related]
17. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic intervention of rheumatoid arthritis bone loss].
Ono K; Ohashi S; Tanaka S
Clin Calcium; 2013 Sep; 23(9):1345-52. PubMed ID: 23999372
[TBL] [Abstract][Full Text] [Related]
18. The effect of disease-modifying antirheumatic drugs (DMARDs) on bone homeostasis in rheumatoid arthritis (RA) patients.
Khoshroo A; Ramezani K; Moghimi N; Bonakdar M; Ramezani N
Inflammopharmacology; 2023 Apr; 31(2):689-697. PubMed ID: 36348208
[TBL] [Abstract][Full Text] [Related]
19. [Control of bone and cartilage lesions in rheumatoid arthritis with TNF inhibitors].
Amano K
Clin Calcium; 2015 Dec; 25(12):1843-50. PubMed ID: 26608860
[TBL] [Abstract][Full Text] [Related]
20. [Anti-RANKL antibody for the treatment of bone and cartilage destruction in rheumatoid arthritis].
Nakayamada S; Tanaka Y
Clin Calcium; 2015 Dec; 25(12):1787-93. PubMed ID: 26608853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
